NCT02757859 is a NA clinical trial of Pancreatectomy in Acinar Cell Carcinoma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.

What drugs are being tested in NCT02757859?

Interventions in NCT02757859: Pancreatectomy, Lavage, Pancreatectomy, Lavage, Pancreatectomy.

What condition does NCT02757859 study?

NCT02757859 studies Acinar Cell Carcinoma, Ampulla of Vater Adenocarcinoma, Cholangiocarcinoma, Duodenal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraductal Papillary Mucinous Neoplasm, Periampullary Adenocarcinoma.

Is NCT02757859 still recruiting?

NCT02757859 is currently recruiting now. Last updated 20 May 2025.

Last reviewed 2025-05-20 · How we verify

NCT02757859

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery

Recruiting now NA Last updated 20 May 2025

What this trial tests

NA trial testing Pancreatectomy in Acinar Cell Carcinoma in 845 participants. Currently enrolling.

Timeline

27 April 2016

Primary endpoint
27 April 2026

27 April 2026

Quick facts

Lead sponsor	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	845
Start date	27 April 2016
Primary completion	27 April 2026
Estimated completion	27 April 2026
Sites	2 locations across United States

Drugs / interventions tested

Pancreatectomy
Lavage
Pancreatectomy
Lavage
Pancreatectomy

Conditions studied

Acinar Cell Carcinoma — all drugs for Acinar Cell Carcinoma →
Ampulla of Vater Adenocarcinoma — all drugs for Ampulla of Vater Adenocarcinoma →
Cholangiocarcinoma — all drugs for Cholangiocarcinoma →
Duodenal Adenocarcinoma — all drugs for Duodenal Adenocarcinoma →

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Who can join

18 and older, any sex, with Acinar Cell Carcinoma or Ampulla of Vater Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized clinical trial studies how well high volume washing of the abdomen works in increasing survival after surgery in patients with pancreatic cancer that can be removed by surgery. High volume washings may remove free floating cancers present after surgery and help prolong survival in patients with pancreatic cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature.
Ghosn M, Kourie HR, El Rassy E, Haddad FG, et al · · 2016 · cited 17× · PMID 27795814 · DOI 10.4251/wjgo.v8.i10.745

Verify or expand the search:

Other trials of Pancreatectomy

Trials testing the same drug.

NCT05453851 — A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatme · Phase 1, PHASE2 · not yet recruiting
NCT07493421 — To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating P · NA · recruiting
NCT06944587 — A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer · recruiting
NCT05841706 — Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients Undergoing a Pancreatectomy for Pancreat · EARLY_PHASE1 · terminated
NCT05325736 — Improvement in Glycemic Response After Bariatric Surgery · recruiting

Other recruiting trials for Acinar Cell Carcinoma

Currently open trials in the same condition.

NCT02834013 — Nivolumab and Ipilimumab in Treating Patients With Rare Tumors · Phase 2 · active not recruiting

Other Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University trials

Trials by the same sponsor.

NCT06974981 — Leveraging Lung Cancer Screening to Optimize Screening Outcomes and COPD Management: COPD in LCS Registry · recruiting
NCT03796884 — Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer · Phase 2 · active not recruiting
NCT03712904 — Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma · Phase 2 · terminated
NCT03807492 — Evaluation and Management for Prostate Oncology, Wellness, and Risk (EMPOWeR) · completed
NCT03477864 — Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progres · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02757859 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Last refreshed: 20 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02757859.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing